Skip to main content
. 2019 Jun 6;55(2):473–487. doi: 10.3892/ijo.2019.4823

Figure 9.

Figure 9

Novel CSE inhibitor I157172 inhibits the VEGF signaling pathway in MDA-MB-231 cells. (A) Blots and (B) graph showing the effect of different concentrations of I157172 on the expression of VEGF. *P<0.05 vs. 0 μM I157172 group; ▲P<0.05 vs. 10 μM I157172 group. (C) Blots and (D) graph showing the effect of different concentrations of I157172 on the PI3K/Akt pathway. *P<0.05 vs. 0 μM I157172 group; ▲P<0.05 vs. 10 μM I157172 group; #P<0.05 vs. 20 μM I157172 group. (E) Blots and (F) graph showing the effect of different concentrations of I157172 on the FAK/paxillin pathway. *P<0.05 vs. 0 μM I157172 group; ▲P<0.05 vs. 10 μM I157172 group; #P<0.05 vs. 20 μM I157172 group. (G) Blots and (H) graph showing the effect of different concentrations of I157172 on the Ras/Raf/ERK1/2 pathway. *P<0.05 vs. 0 μM I157172 group; ▲P<0.05 vs. 10 μM I157172 group. CSE, cystathionine-γ-lyase; VEGF, vascular endothelial growth factor; PI3K, phosphatidylinositol 3-kinase; Akt, protein kinase B; FAK, focal adhesion kinase; Ras, rat sarcoma; Raf, rapidly accelerated fibrosarcoma; ERK, extracellular signal-regulated protein kinase; pERK, phosphorylated ERK; pAkt, phosphorylated Akt.